BIO-RAD LABORATORIES, INC. — Director's Dealing 2021

Aug 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-RAD LABORATORIES, INC. (BIO BIOB)
CIK: 0000012208
Period of Report: 2021-08-04

Reporting Person: Daskal Ilan (EVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-04	Bio-Rad A Common Stock	M	1400	$309.84	Acquired	2307	Direct
2021-08-04	Bio-Rad A Common Stock	S	857	$750.85	Disposed	1450	Direct
2021-08-04	Bio-Rad A Common Stock	S	954	$751.98	Disposed	496	Direct
2021-08-04	Bio-Rad A Common Stock	S	489	$753.32	Disposed	7	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-04	Non-Qualified Stock Option (right to buy)	$309.84	M	1400	Disposed	2029-04-08	Bio-Rad A Common Stock (1400)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.77 to $751.39, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $751.98 to $752.22, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $753.28 to $753.40, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The option, representing a right to purchase a total of 3,500 shares, became exercisable in five equal annual installments beginning on April 8, 2020, which was the first anniversary of the date on which the option was granted.